Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Association of oral calcitriol with improved survival in nondialyzed CKD.

Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B.

J Am Soc Nephrol. 2008 Aug;19(8):1613-9. doi: 10.1681/ASN.2007111164. Epub 2008 May 7.

3.

Active vitamin D and survival.

Wolf M.

J Am Soc Nephrol. 2008 Aug;19(8):1442-3. doi: 10.1681/ASN.2008060595. Epub 2008 Jul 9. No abstract available.

4.

Association of activated vitamin D treatment and mortality in chronic kidney disease.

Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K.

Arch Intern Med. 2008 Feb 25;168(4):397-403. doi: 10.1001/archinternmed.2007.110.

PMID:
18299495
6.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
7.

Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD.

Negri AL.

Nephrol Dial Transplant. 2009 Feb;24(2):341-4. doi: 10.1093/ndt/gfn624. Epub 2008 Nov 7. Review. No abstract available.

8.

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.

Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.

Clin Nephrol. 2009 Jun;71(6):660-8.

PMID:
19473635
9.

Variation in oral calcitriol response in patients with stages 3-4 CKD.

Shoben AB, Levin G, de Boer IH, Yeung C, Watnick S, Ayers E, Kestenbaum B.

Am J Kidney Dis. 2012 May;59(5):645-52. doi: 10.1053/j.ajkd.2011.11.041. Epub 2012 Jan 29.

10.

Vitamin D treatment in chronic kidney disease.

Andress DL.

Semin Dial. 2005 Jul-Aug;18(4):315-21. Review.

PMID:
16076355
11.

Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.

Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H.

Ren Fail. 2008;30(4):407-10. doi: 10.1080/08860220801964210.

PMID:
18569914
12.

Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.

Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.

Clin Exp Nephrol. 2005 Sep;9(3):238-43.

PMID:
16189633
13.

Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.

Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.

Nephron Clin Pract. 2008;110(1):c58-65. doi: 10.1159/000151534. Epub 2008 Aug 25.

PMID:
18724068
14.

[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].

Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R.

Clin Calcium. 2006 May;16(5):847-51. Japanese.

PMID:
16679628
15.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
16.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
17.

Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.

Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A.

Am J Nephrol. 2013;37(3):239-48. doi: 10.1159/000346846. Epub 2013 Mar 5. Review.

18.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
19.

Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.

Hostutler RA, DiBartola SP, Chew DJ, Nagode LA, Schenck PA, Rajala-Schultz PJ, Drost WT.

J Vet Intern Med. 2006 Nov-Dec;20(6):1307-13.

20.

Local calcitriol injections as a suppressive treatment of secondary hyperparathyroidism in chronic dialysis patients.

Junik R, Polaáska M, Manitius J, Doroszewski W, Sypniewska G, Gruszka M.

Ren Fail. 2007;29(8):941-5.

PMID:
18067038
Items per page

Supplemental Content

Write to the Help Desk